EastBuy, the cross-border sub-brand under EAST BUY, has confirmed the arrival of its Coenzyme Q10 supplement on the shelves of Australian pharmacy retail outlets. The product, manufactured in Australia, has been officially registered with the Therapeutic Goods Administration (TGA), meeting stringent local regulatory standards.

The supplement operates under a dual-management framework, combining Australia's regulatory oversight with EAST BUY's own quality control protocols. The formula was developed by the company's Chinese product team, which also manages the entire production quality process. Manufacturing adheres strictly to TGA guidelines, ensuring compliance at every stage. Under the TGA system, the product is subject to scheduled stability testing, including potency assays and contaminant screenings at multiple time points throughout its shelf life. EAST BUY has disclosed that it has enrolled the product in a continuous stability testing program, guaranteeing that all functional ingredients maintain their declared levels across the two-year shelf life.

Following the completion of TGA filing, local production in Australia, and the initial overseas sales rollout, the product is now set for release to domestic Chinese consumers. According to official information from EAST BUY, the EastBuy Coenzyme Q10 will premiere in an exclusive overseas launch segment during the "EAST BUY Australia Tour" livestream on September 16. After that, orders will be processed and shipped from customs-supervised bonded warehouses, with full logistics tracking available for customers.